BioPharma, Pharma

Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal

Pfizer gains global rights, excluding Greater China, to three in vivo CAR-T cell therapies from Starna Therapeutics in preclinical development for undisclosed autoimmune diseases. It’s the latest in a series of big pharma business deals involving in vivo cell therapy assets and platform technologies.

Pfizer wasn’t part of the first wave of cell therapies, but the pharmaceutical company is gaining an opportunity to be part of the next generation of these medicines by securing rights to three preclinical Starna Therapeutics programs in development for autoimmune diseases.

Under terms of the agreement announced Wednesday, Pfizer is paying $330 million up front for global rights, excluding Greater China, to these in vivo programs. Pfizer also gains rights to use Starna’s proprietary in vivo cell therapy technology for applications in inflammation and immunology as well as oncology. Specific targets and indications for the assets covered under the pact were not disclosed.

The first CAR-T therapies reached the market as personalized cancer treatments made by engineering a patient’s own T cells to go after cancer cells. These treatments are manufactured in an expensive, multi-step process. As a field, cell therapy is becoming even more personalized with R&D focused on in vivo treatments in which the therapeutic cells are produced inside the patient’s body, doing away with the manufacturing and preparation steps of ex vivo therapies. Companies developing these in vivo treatments are also expanding the scope of cell therapy to immunology.

presented by

Suzhou, China-based Starna develops RNA-based medicines delivered by lipid nanoparticles (LNPs). These particles are a common way for delivering RNA therapies, but they preferentially go to the liver. Starna has technology that engineers LNPs to address targets beyond the liver. This technology supports in vivo CAR-T therapies, which are made by the targeted delivery of an RNA payload that reprograms a patient’s cells to become a cell therapy. Meanwhile, Pfizer’s experience with RNA products is through Comirnaty, the messenger RNA-based Covid-19 vaccine it developed in partnership with BioNTech.

“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short,” Michael Vincent, chief inflammation & immunology officer, Pfizer, said in a prepared statement. “Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches.”

Pfizer’s top immunology drug is Xeljanz, a small molecule JAK inhibitor with approvals in several indications. Xeljanz generated more than $1 billion in sales last year, but its key patents have already expired. While the Starna therapies give Pfizer additional opportunity in immunology, in vivo cell therapy is becoming competitive. This year, Eli Lilly and Johnson & Johnson have each added vivo cell therapy candidates via busines deals. Last year, AstraZeneca, AbbVie, Gilead Sciences, and Bristol Myers Squibb joined the in vivo cell therapy race via acquisitions.

Pfizer will lead clinical development of the Starna therapies outside of Greater China. The pharma company added that it plans to handle manufacturing of the drug for clinical trials at its U.S. facilities. If the licensed assets lead to approved products, Pfizer has exclusive rights to commercialize them outside of Greater China.

presented by

Beyond the $330 million upfront payment, Pfizer could pay out up to $2.3 billion more if the Starna assets achieve development and commercial milestones, plus royalties from sales of any approved products. The Starna pact gives Pfizer the option to exclusively license compounds created under a separate R&D collaboration as well as an option to expand the territory covered by the agreement to include Greater China.

Photo: Dominick Reuter/AFP, via Getty Images